This study compared the penetration of moxalactam and cefazolin into the human atrial appendage after simultaneous administration of both drugs by two routes. Nineteen adult patients scheduled for coronary vein bypass surgery randomly received 10 mg of moxalactam and cefazolin per kg by either the intramuscular or intravenous (bolus) route on administration of anesthesia. Concentrations of cefazolin in serum were significantly greater than concentrations of moxalactam at all times for both routes of administration. There were no significant differences, however, in the concentration of these drugs in atrial appendages, although concentrations of both agents administered intravenously were significantly greater than of drugs administered intramuscularly. (19.3 ± 10.3 and 21.0 ± 11.0 jxg/g intravenously versus 8.3 ± 3.6 and 10
This study compared the penetration of moxalactam and cefazolin into the human atrial appendage after simultaneous administration of both drugs by two routes. Nineteen adult patients scheduled for coronary vein bypass surgery randomly received 10 mg of moxalactam and cefazolin per kg by either the intramuscular or intravenous (bolus) route on administration of anesthesia. Concentrations of cefazolin in serum were significantly greater than concentrations of moxalactam at all times for both routes of administration. There were no significant differences, however, in the concentration of these drugs in atrial appendages, although concentrations of both agents administered intravenously were significantly greater than of drugs administered intramuscularly. (19.3 ± 10.3 and 21.0 ± 11.0 jxg/g intravenously versus 8.3 ± 3.6 and 10.1 ± 3.2 ,ug/g intramuscularly for moxalactam and cefazolin, respectively).
We recently reported that the pharmacokinetics of moxalactam and cefazolin in normal adults are as distinctive after simultaneous intravenous infusion as they are after separate infusion, and we proposed that the method of simultaneous administration may have significant advantages for comparisons of the penetration of antibiotics into tissue (8) . This study was designed to compare the atrial appendage penetration of moxalactam with that of cefazolin after simultaneous administration by either the intravenous (i.v.) or the intramuscular (i.m.) route.
MATERIALS AND METHODS
Subjects and drug administration. A total of 19 adult patients, 15 males and 4 females, ranging from 45 to 76 years in age and from 52 to 111 kg in weight, scheduled for coronary vein bypass surgery, were included in this study and gave informed consent. None had a history of bypass surgery or allergy to ,B-lactam antibiotics. All patients had normal serum creatinine levels (<1.4 mg/dl) except two (1.5 and 2.9 mg/dl), and all patients had normal serum bilirubin levels ('1.1 mg/ dl) at the time of surgery. Patients were allocated by a table of random numbers to receive both antibiotics by either the i.m. route (9 patients) or the i.v. route (10 patients).
Lot 3TU65A of cefazolin sodium and lot CT-4765-OM of moxalactam disodium (Eli Lilly & Co., Indianapolis, Ind.) were used in this study. Immediately before surgery, the antibiotics were reconstituted with bacteriostatic normal saline or sterile water for injec-* To whom requests for reprints should be addressed. (804) 786-7625 tion according to the manufacturer's recommendation (3.0 and 2.5 ml/g for moxalactam and cefazolin, respectively). The resulting assumed concentrations were 270 mg/ml for moxalactam and 330 mg/ml for cefazolin. A dose of 10 mg of each drug per kg was given to each subject. Both moxalactam and cefazolin were given at the same time into either a rapidly running i.v. line over 1 to 2 min (bolus study) or separately into each deltoid muscle shortly after beginning anesthesia. The mean time (with standard deviation) between drug administration and removal of the atrial appendage was 40.9 ± 12.7 min. The mean dose received (with standard deviation) was 793 ± 147 mg. Blood was obtained from an indwelling arterial line before antibiotic administration, at 15 and 30 min after administration, and simultaneously with the removal of the atrial appendage at the time of right heart cannulation. Serum, separated by centrifugation as soon as clotting was complete, was maintained at -40°C until assayed for antibiotic content.
Antibiotic assay. The concentrations of moxalactam and cefazolin in serum were determined simultaneously by a high-performance liquid chromatographic assay according to the method of Diven et al. (2) , modified as previously described (8) .
The atrial appendage was rinsed with distilled water and allowed to blot dry. A portion was weighed accurately and processed immediately or stored at -40°C for later processing. To extract the antibiotics, the tissue sample was added to 1.0 to 1.5 ml of distilled water (accurately measured) and then homogenized in an ice bath for 30 to 60 s (Tissue-mizer, Tekmar Corp., Cincinnati, Ohio). The homogenate was centrifuged for 10 min, and the supernatant was separated for assay. Moxalactam was found to be stable and virtually 100%'o recoverable when a solution of known moxalactam concentration was homogenized with a moxa- lactam-free atrial appendage sample. Cefazolin was assumed to be stable based upon previously published work (6) . Two additional extractions of the remaining pellet were performed. However, it was found that the small concentrations detected in the second extraction could be accounted for by the known volume of the first extraction remaining on the homogenization probe. Therefore, only the assay results from the first extraction are reported. The high-performance liquid chromatographic assay for moxalactam and cefazolin in atrial appendage extracts was performed just as it was for the serum assays, except that the standard curve was prepared to encompass the range of 0 to 10 p.g/ml. The lowest detectable concentration of both drugs was 0.25 ,ug/ml. The day-to-day coefficient of variation for a control concentration of 1.0 FLg/ml was 7% for cefazolin and 5% for moxalactam.
To assess the extent to which contamination of the tissue sample with blood contributed to tissue levels of the antibiotic, a portion of the first extract for each subject was analyzed for hemoglobin concentration by a spectrophotometric analysis of cyanmethemoglobin performed on a hemoglobinometer (Coulter Electronics, Inc., Hialeah, Fla.) as previously described (4, 6 
RESULTS
Concentrations of cefazolin in serum were significantly greater than concentrations of moxalactam at all times for both routes of administration (Table 1) . Likewise, concentrations of each drug in serum were significantly greater after i.v. infusion than after i.m. injection at all time periods (Table 1 ). The concentrations of both moxalactam and cefazolin in atrial appendages were significantly greater after i.v. infu-sion than after i.m. injection (Table 1) . There was no significant difference, however, between the concentrations of the drugs in atrial appendages for each route of administration. There was also no significant linear relationship between the time to removal of the atrial appendage and the antibiotic tissue concentration.
DISCUSSION
The advantages of simultaneous administration of two antimicrobial agents for comparative studies of their tissue penetration have been identified recently (8) . Half as many subjects are required for the same number of datum points (tissue concentrations), pairing of all data permits the use of more powerful statistical tests, many complicating factors are eliminated (e.g., differences in time of removal of tissue), concentrations of both drugs can be measured simultaneously if high-performance liquid chromatographic assay is available, and an antibiotic with relatively poor activity against a specific pathogen (e.g., moxalactam versus Staphylococcus aureus [3] ) can still be studied when given with a reliable prophylactic agent. The disadvantages of this method are that the pharmacokinetics of drugs in combination must be the same as when they are delivered separately, and the assay used must be able to measure each drug precisely and without influence from the other drug. Since competition for tubular secretion would be the most likely mechanism for pharmacokinetic interference in serum, the lack of significant secretion for moxalactam may explain the independence of cefazolin and moxalactam (5). Although pharmacokinetic independence in serum for these two agents has been demonstrated (8), it is possible that there is competition between these two antibiotics for tissue penetration. Since we did not employ a control group receiving only moxalactam or cefazolin, we cannot be certain that the tissue concentrations of one antibiotic were not altered by the presence of the other. However, since penetration into an unspecialized tissue such as an atrial appendage is probably a passive diffusion process in which competition would not be expected, it seems likely that moxalactam and cefazolin penetrated independently of each other (1) .
The finding that moxalactam penetrated into heart muscles as well as cefazolin did, despite significant differences in serum concentrations, is of interest. The reason for this is not immediately apparent, although differences in protein binding (approximately 40% for moxalactam [7] versus 85% for cefazolin) and lipophilicity are possible explanations (1) . However, it must be noted that due to the relatively poor in vitro activity of moxalactam against staphylococci (3) and its relatively high cost, moxalactam would not be indicated as a prophylactic agent when these organisms are the most likely pathogens, e.g., in cardiac or orthopedic surgery.
The route of administration had a significant effect on the penetration of both cefazolin and moxalactam into atrial appendages. Thus, when cefazolin is given on administration of anesthesia for prophylaxis in cardiovascular surgery, it may be preferable to administer the antibiotic as an i.v. bolus instead of by the i.m. route if the highest concentrations in serum and tissues are desired.
